Bilthoven Biologicals
Pascal de Jong is an experienced professional in the field of pharmaceuticals and biotechnology, currently serving as the Process Validation Manager at Bilthoven Biologicals since May 2017, following a role as an R&D Scientist. Prior experience includes positions as an Associate Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson from January 2014 to April 2017 and at Crucell from September 2010 to January 2014. Pascal de Jong holds a Master of Science (MSc) in Pharmaceutics and Drug Design from Utrecht University (2008-2010) and a Bachelor of Science (BSc) in Molecular Biology from HU University of Applied Sciences Utrecht (2003-2008).
This person is not in any offices
Bilthoven Biologicals
About Bilthoven Biologicals Bilthoven Biologicals is a biopharmaceutical company which produces Inactivated Polio Vaccines (IPV), Tetanus Vaccines, Diphtheria-Tetanus-Polio Vaccines (DT-PV) and Bacillus Calmette-Guérin (BCG) for the treatment of bladder cancer. We deliver our vaccines to UNICEF, with which we support the World Health Organisation (WHO) to eradicate polio. Bilthoven Biologicals has been part of the Cyrus Poonawalla Group since 2012, the world’s largest vaccine producer and employs more than 500 employees. www.bbio.nl | www.werkenbijbbio.nl | https://www.bbio.nl/en/what-we-produce/report-side-effects/ Over Bilthoven Biologicals Bilthoven Biologicals is een biofarmaceutisch bedrijf dat geïnactiveerde polio vaccins (IPV), Tetanus vaccins, Difterie-Tetanus-Polio vaccins (DT-IPV) produceert en Bacillus Calmette-Guérin (BCG) voor de behandeling van blaaskanker. Wij leveren onze vaccins aan UNICEF, waarmee wij de Wereldgezondheidsorganisatie (WHO) ondersteunen bij het uitroeien van polio. Bilthoven Biologicals is sinds 2012 onderdeel van de Cyrus Poonawalla Group, de grootste vaccinproducent ter wereld en heeft ruim 500 medewerkers. www.bbio.nl | www.werkenbijbbio.nl | https://www.bbio.nl/wat-wij-maken/bijwerkingen-melden/